Most Volatile Stocks: Accenture (NYSE:ACN), Total System Services (NYSE:TSS), Epizyme (NASDAQ:EPZM)
Accenture plc (NYSE:ACN) stock reports decrease of -0.56% in last trading session and closed at a price of $118.69. Accenture (ACN) received that a one-year base and three one-year options, worth a total of $64 million from the TSA to modernize, enhance and maintain over 70 TSA enterprise applications using Agile and DevOps software development practices. The contracts calls for Accenture Federal Services to provide a range of IT services led by Agile development teams in the TSA’s existing technology environment while supporting the transformation of its core IT applications.
Its 52-week range quite noticeable, lower range was $11.51% and hit highest level of $-5.22%. The overall volume in the last trading session was 1.94 Million shares. How NYSE:ACN Become Volatile Stock? Find Out Here
Total System Services, Inc. (NYSE:TSS) has 182.94 million outstanding shares. Total System Services Inc. (TSS) declared on Tuesday that its Q1 earnings of $105.9 million. The Columbus, Georgia-based company said it had profit of 57 cents per share. Earnings, adjusted for amortization costs and stock option expense, were 82 cents per share.
The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of 77 cents per share. The electronic payment services provider posted revenue of $1.18 billion in the period, which fell short of Street forecasts. Three analysts surveyed by Zacks expected $1.21 billion. Total System expects full-year earnings in the range of $3.16 to $3.26 per share, with revenue in the range of $3.3 billion to $3.4 billion.
The firm stock closed at $54.31 by surging 0.93% in last trading day. As the returns are concern, return on equity was recorded 15.80% and firm surged its return on investment 7.50% while its return on asset stayed at 5.20%. How Factors Effect On Stocks’ Performance? Read Considerable Report Here
Shares of Epizyme, Inc. (NASDAQ:EPZM) at the time when day-trade ended the stock finally soared 17.11% to close at $17.45. Epizyme (EPZM) reported that FDA has granted Fast Track designation to tazemetostat for the treatment of patients with relapsed or refractory follicular lymphoma, either wild type EZH2 or with EZH2 activating mutations.
The firm also announces that interim efficacy and safety data from all five study cohorts in its ongoing Phase 2 study of tazemetostat in patients with relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma (:DLBCL) has been selected for a plenary session on Wednesday, June 14, 2017 at 2:00 p.m. CET at the International Conference on Malignant Lymphoma.
Results from a biomarker study of tazemetostat in patients with NHL will be presented in a poster session during ICML. The Company plans to hold a conference call to discuss these clinical findings on Wednesday, June 14 at 10:30 a.m. ET.
Shares price isolated positively from its 50 days moving average with 16.41% and remote positively from 200 days moving average with 54.95%. Why Investors Right to Know NASDAQ:EPZM Performance? Get Your Free Report Here